- Home
- PTON vs MRUS Comparison
PTON vs MRUS Comparison
Compare PTON & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTON
- MRUS
- Stock Information
- Founded
- PTON 2012
- MRUS 2003
- Country
- PTON United States
- MRUS Netherlands
- Employees
- PTON N/A
- MRUS N/A
- Industry
- PTON Recreational Games/Products/Toys
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- PTON Consumer Discretionary
- MRUS Health Care
- Exchange
- PTON Nasdaq
- MRUS Nasdaq
- Market Cap
- PTON 3.0B
- MRUS 3.6B
- IPO Year
- PTON 2019
- MRUS 2016
- Fundamental
- Price
- PTON $9.06
- MRUS $44.36
- Analyst Decision
- PTON Hold
- MRUS Strong Buy
- Analyst Count
- PTON 18
- MRUS 10
- Target Price
- PTON $6.34
- MRUS $86.70
- AVG Volume (30 Days)
- PTON 25.1M
- MRUS 434.2K
- Earning Date
- PTON 10-31-2024
- MRUS 10-31-2024
- Dividend Yield
- PTON N/A
- MRUS N/A
- EPS Growth
- PTON N/A
- MRUS N/A
- EPS
- PTON N/A
- MRUS N/A
- Revenue
- PTON $2,690,700,000.00
- MRUS $35,932,000.00
- Revenue This Year
- PTON N/A
- MRUS N/A
- Revenue Next Year
- PTON $1.63
- MRUS $52.49
- P/E Ratio
- PTON N/A
- MRUS N/A
- Revenue Growth
- PTON N/A
- MRUS N/A
- 52 Week Low
- PTON $2.70
- MRUS $22.26
- 52 Week High
- PTON $9.20
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- PTON 68.48
- MRUS 32.24
- Support Level
- PTON $7.31
- MRUS $42.30
- Resistance Level
- PTON $8.68
- MRUS $53.49
- Average True Range (ATR)
- PTON 0.59
- MRUS 2.29
- MACD
- PTON -0.03
- MRUS -1.04
- Stochastic Oscillator
- PTON 92.84
- MRUS 15.70
About PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of bike and tread and related accessories sales, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue is generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from the International markets.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.